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Aggregation of the b-amyloid (Ab) peptide into toxic oligo-
mers is considered the primary event in the pathogenesis
of Alzheimer’s disease. Previously generated peptides and
mimetics designed to bind to amyloid fibrils have encoun-
tered problems in solubility, protease susceptibility and the
population of small soluble toxic oligomers oligomers. We
present a new method that opens the possibility of deriving
new amyloid inhibitors. The intracellular protein-fragment
complementation assay (PCA) approach uses a semi-ra-
tional design approach to generate peptides capable of
binding to Ab. Peptide libraries are based on Ab regions
responsible for instigating amyloidosis, with screening and
selection occurring entirely inside Escherichia coli.
Successfully selected peptides must therefore bind Ab and
recombine an essential enzyme while permitting bacterial
cell survival. No assumptions are made regarding the
mechanism of action for selected binders. Biophysical
characterisation demonstrates that binding induces a no-
ticeable reduction in amyloid. Therefore, this amyloid-
PCA approach may offer a new pathway for the design of





Given the strong link between b-amyloid (Ab) deposition and
Alzheimer’s disease (AD), a promising therapeutic approach
is the prevention of Ab aggregation. An attractive strategy is
the use of small molecules that modulate Ab aggregation (see
Arkin and Wells, 2004; Doig, 2007; Berg, 2008 and references
therein) and peptide-based ‘b-sheet breakers’ (BSBs) (Ghanta
et al., 1996; Soto et al., 1996, 1998; Tjernberg et al., 1996;
Findeis et al., 1999; Poduslo et al., 1999; Tjernberg et al.,
1999; Hughes et al., 2000; Gordon et al., 2001; Kokkoni et al.,
2006; Sciarretta et al., 2006). These have focused on two core
amyloidogenic ‘recognition elements’; residues 15–21 and
25–35 of the Ab parent peptide (Tjernberg et al., 1996;
Hughes et al., 2000; Kokkoni et al., 2006). These regions are
of particular importance since they are responsible for instigat-
ing Ab self-association and aggregation and even form
amyloid in isolation (Tjernberg et al., 1996). Furthermore,
solid state nuclear magnetic resonance data predict these rec-
ognition elements form a b-hairpin, providing the structural
basis for amyloidogenesis in the parent peptide (Petkova et al.,
2002; Tycko, 2011). Therefore, many strategies have focused
on modification of these regions such that they retain the
ability to bind Ab but prevent amyloid formation, for
example, by introducing either a blocking group or charge to
these short sequences. However, issues have been identified
with solubility, protease susceptibility and population of toxic
small soluble oligomers. For example, Tjernberg et al. (1996)
demonstrated that the pentapeptide Ac-KLVFF-NH2 (Ab16 –
20), despite forming fibrils itself, binds residues 25–35 of
Ab1 – 42 and prevents fibril formation. Other peptides based
around regions 25–35 and 38–42 have also been identified
with some encouraging results (Hughes et al., 2000; Hetenyi
et al., 2002; Fulop et al., 2004; Kokkoni et al., 2006). Soto
et al. (1996, 1998) have focused on the 15–21 core recognition
element with a series of peptides based on residues Ab17 – 21.
However, other groups have shown that clearance of large
amyloid fibrils can lead to the population of small cytotoxic
intermediates (Lowe et al., 2001). Therefore, promising mole-
cules must be capable of preventing the population of amyloid
fibres while avoiding the generation of intermediary toxic
species. To date, this challenge has hampered the search for
BSB peptides.
We present a novel variation of the protein-fragment com-
plementation assay (PCA) methodology to generate and
screen peptide libraries in vivo (Pelletier et al., 1998; Mason
et al., 2006; Remy et al., 2007). Using the PCA approach to
select peptides capable of binding to amyloid has not been
published to date, although its potential use in this role has
been previously speculated (Michnick et al., 2011). Briefly, at
the genetic level the Ab target protein is fused to one-half of
an essential enzyme, murine dihydrofolate reductase
(mDHFR), with a peptide library fused to the other half. If a
library member interacts with Ab, mDHFR is recombined to
yield a colony under selective conditions (Fig. 1). Since this
assay is carried out via transformation of bacterial cells, the
entire process is intracellular and no assumptions are made
regarding the mechanism of antagonist action or which
amyloid state becomes populated during selection. PCA there-
fore functions by screening and identifying library members
that bind with the highest affinity to Ab while additionally
selecting against cells that display reduced growth rates. This
reduction is due to the inherent propensity for Ab to aggregate
and the associated toxicity of fibrillar material to bacteria
(Sharpe et al., 2005; Soscia et al., 2010). Although transform-
ation of cells limits the realistic library size to 106 members,
PCA has other desirable attributes relative to in vitro library
screening systems (Orner et al., 2006) that aid in
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circumventing potential barriers to further development. For
example, PCA has been previously shown to remove mole-
cules with undesirable properties from the library, such as
those that are too hydrophobic and hence insoluble, those
tagged for degradation and those susceptible to protease
action. In addition, non-specific off-target interactions in the
crowded environment of the cytoplasm would preclude recom-
bination of DHFR making this approach a better analogue of
the in vivo milieu than obtainable from an in vitro system.
There are three possible outcomes for any given library
member when screened:
(1) Library members bind Ab, reduce its toxicity and re-
combine mDHFR, to confer cell survival.
(2) Library members bind Ab and recombine mDHFR
but either populate or do not prevent population of a
toxic species. These result in reduced cell growth
relative to (1), or cell death.
(3) Library members with no affinity for Ab and there-
fore no effect on amyloid formation will not recom-
bine mDHFR, resulting in cell death.
In outcomes (1) or (2), the Ab target could be monomeric
or oligomeric; peptides that bind either form will lead to
mDHFR reassembly. We find the PCA-derived peptides to be
capable of binding b-amyloid 1–42 variant (Ab1 – 42) and re-
ducing amyloid load. Selected peptides show promise in
reversing and breaking down preformed fibrils. These studies
have successfully generated a number of lead peptide
sequences as a proof of principle for this generalised technique
to provide a scaffold for future drug candidates.
Material and methods
Single-step selection PCA
Escherichia coli XL-1 cells were used for construction and
cloning of libraries as described previously (Mason et al.,
2006). Firstly, pES300d-Ab25–35 target and pREP4 (Qiagen;
for expression of the lac repressor protein) were co-transformed
into BL-21 gold cells (Stratagene) and plated onto Luria Broth
(LB) agar with the appropriate antibiotics (kanamycin (Kan)
and chloramphenicol (Cm)). These cells were next made elec-
trocompetent before transformation with pES230d library
plasmid. Transformed cells were plated onto three different
media; 1/20th of the cells were plated onto LB agar with three
antibiotics (Kan, ampicillin (Amp) and Cm) as a positive
control of transformation efficiency. A further 1/20th of the so-
lution was plated onto M9 minimal medium agar containing
1 mg/ml trimethoprim and the same three antibiotics as a nega-
tive control. Finally, the remaining 90% of transformed cells
were plated onto M9 minimal agar in the presence of the three
antibiotics, 1 mg/ml trimethoprim and 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG), to induce expression of the
two DHFR fragment fused peptides. This single-step PCA
selection typically led to 50–100 colonies from initial
libraries of 8000 and 160 000, meaning that at least 99%
of all library members are removed at this stage owing to
their inability to bind Ab or rescue cell growth. Expression of
Ab25–35-DHFR2 target protein in the soluble fraction was veri-
fied by western blotting (see Supplementary information).
Competition selection PCA
To increase selection stringency, growth competition experi-
ments were undertaken. Selected colonies were pooled from
the plate and grown in M9 minimal media under selective con-
ditions (containing Kan, Amp, Cm, trimethoprim and IPTG)
and serially diluted over 5–10 passages (p1–p10). Using
these sequential rounds of competition selection, subtle differ-
ences in growth rate can become amplified, increasing the
stringency of selection relative to the single-step method.
Competition selection therefore allows the most effective 1–2
sequences to be isolated from the 50–100 Ab binders that are
initially identified during single-step selection. At each
passage glycerol stocks were prepared and sequencing results
were obtained (GATC Biotech, London, UK) for DNA pools
as well as individual colonies. For each passage, 50 ml of
liquid culture was added to 50 ml of fresh M9 minimal media,
resulting in an approximate OD600 of 0.01. Cells were incu-
bated at 378C until an OD600 of 0.4 was reached (typically
2–3 days), before moving to the next passage.
Fig. 1. The PCA for amyloid systems. Library members that bind to Ab25 – 35 recombine murine DHFR (PDB: 2FZJ) and lead to a colony under selective
conditions (bacterial DHFR is specifically inhibited using trimethoprim). Subsequent competition selection in liquid media isolates winners of highest efficacy.
Those library members that bind the target and are able to confer faster growth rates by reducing the toxic effects of the amyloid protein most effectively will be
selected. Since the assay is performed in the cytoplasm of E.coli, any non-specific, unstable, aggregation prone (insoluble), protease susceptible members are
removed.
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Peptides KAT, L2P1a, L2P1b, L2P2a, L2P2b and a positive
control from the literature, iAb5 (Soto et al., 1996), were
obtained by Peptide Protein Research (Fareham, UK) as pure
lyophilised peptides and weighed using an analytical balance.
Stock solutions of 1 mM concentration were subsequently
dissolved in ultrapure water. At this concentration of a
2–200-fold excess of that used in inhibition and reversal
experiments, no aggregation or precipitate was observed. In
addition bioinformatics tools (e.g. Waltz (Maurer-Stroh et al.,
2010), Amylpred (Frousios et al., 2009), Pasta (Trovato et al.,
2007), Zyggregator (Tartaglia and Vendruscolo, 2008) and
Tango (Fernandez-Escamilla et al., 2004)) did not predict any
of the peptides to contain amyloidogenic sequences or
aggregate in isolation. Finally, dye-binding experiments dem-
onstrate that these sequences do not bind thioflavin-T (ThT)
and form random-coil like species in isolation using circular
dichroism (CD) (see Supplementary information).
See Supplementary information for additional methods.
Results
We have employed protein-fragment complementation screen-
ing using peptide libraries (Mason et al., 2006; Remy et al.,
2007) to derive peptides capable of binding to Ab. PCA librar-
ies were initially screened and selected on M9 minimal agar
plates. Following this initial ‘single-step’ selection, colonies
underwent ‘competition selection’ where they were pooled
and grown before dilution. This process was repeated multiple
times as ‘passages’ to select for a unique clone (Fig. 1). In this
process, 1–2 binders were found to elicit the fastest bacterial
growth and dominate the bacterial pool (see below). DNA se-
quencing continued throughout passaging until selection
arrived at one discrete peptide.
Library 1 generation
PCA was undertaken with Ab25 – 35 target using libraries based
on Ab29 – 35 (GAIIGLM), a region of the molecule known to
aggregate into toxic fibrils in isolation (Pike et al., 1995;
Hughes et al., 2000; Hung et al., 2008) and therefore a valid
starting point for deriving Ab binders capable of inhibiting ag-
gregation. The first library incorporated three fully randomised
residues at positions 31–33, generating GAxxxLM, and corre-
sponding to a library size of 8000. Single-step selection on M9
plates was undertaken followed by competition selection in
M9 liquid media, resulting in one clean sequencing result by
passage six, GAKATLM (Fig. 2).
Library 2 generation
The first PCA winner (termed ‘KAT’) was used as a scaffold
for the design of a second library. With residues 31–33 fixed
as KAT, two residues on either sides at positions 29–30 and
34–35 were fully randomised (xxKATxx), representing a
160 000 member library (Fig. 2). Therefore, using Ab29 – 35 as
an initial design scaffold two completely unrelated sequences
were subsequently derived. After 12 passages, equal prefer-
ence was observed for the two sequences: L2P1 (FSKATSN;
Table I) and L2P2 (PVKATTA; Table I). In this instance two
Fig. 2. Schematic of library and sequence selection technique. The library is based on the Ab29 –35 region with residues 31–33 completely randomised to all
amino acid options (i.e. 8000 members) in the first library. Having identified the winner GAKATLM from the first PCA, a second library with residues 29–30 and
34–35 randomised (i.e. 160 000 members) was created. This resulted in two sequences, L2P1 (FSKATSN) and L2P2 (PVKATTA). Shown also are sequencing
results for single-step selections and the final passages of competition selection. For the first library, randomised residues 31–33 settled on the sequence
‘GAKATLM’ as confirmed by passage 6. For the second library, two sequences were present during sequencing of individual colonies, PVKATTA and
FSKATSN. While the second appeared to dominate the bacterial pool from passages 7–10 and was verified by sequencing individual colonies, the first was also
observed in individual colonies throughout the competition selection process.
Intracellular library selected Ab interacting peptides
Page 3 of 8






versions of each peptide were synthesised: (i) with selected
residues only (L2P1a/L2P2a), and (ii) which retained addition-
al amino acids from restriction sites during cloning into the
pES230d vector (L2P1b/L2P2b).
Peptide characterisation
PCA-derived peptide sequences (Table I) were synthesised and
characterised using a number of experiments that included ThT
dye binding, CD, oblique angle fluorescence (OAF) microscopy
and transmission electron microscopy (TEM), in order to dem-
onstrate that the peptides do not aggregate in isolation (see
Supplementary information) and are able to reduce aggregation
and/or breakdown preformed fibrils. In addition, growth compe-
tition assays in E.coli under PCA conditions in M9 media and
an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay using PC12 cells, both with the Ab1–42 parent
peptide, were carried out. The growth competition experiments
demonstrate that peptides bind to Ab and affect its toxicity to
bacteria. MTT experiments were used to establish if the pep-
tides also reduced Ab toxicity in the context of mammalian
cells by adding Ab1–42 oligomers to PC12 cells in the presence
of PCA selected peptides.
Tht binding indicates a reduction in fibril load
To determine the ability of PCA-derived peptides to reduce
fibril assembly (inhibition) and/or breakdown preformed fibrils
(reversal), ThT binding was used to quantify amyloid species.
Firstly, Ab1–42 was rendered monomeric (Zagorski et al.,
1999) and aggregated into amyloid by resuspending and incu-
bating at 378C. For the inhibition assay, peptides were added on
Day 0 and tested daily over a 3-day period. iAb5, known to
perform well in ThT assays, was also used as a positive control
peptide (Soto et al., 1998). Figure 3 shows the average of four
different Ab : peptide ratios. The ThT signal was reduced in all
instances indicating that peptides are able to bind Ab1–42 and
reduce aggregation levels. As expected, the positive control
iAb5 peptide (Soto et al., 1998) was able to reduce the ThT







The first library consisted of 8000 members and was fully randomised with all
amino acid options at positions 31–33 of the Ab25 – 35 scaffold, resulting in the
selection of ‘KAT’ at these positions after six rounds of competition selection.
A second library consisting of 160 000 members was fully randomised at
positions 29–30 and 34–35 with the KAT sequence from the first selection
fixed. L2P1 and L2P2 sequences are based on the original KAT sequence.
Addition of AS/GAP sequences reflect additional residues present in the
expressed protein. Acetylation and amidation of the protein was added to
mimic the polypeptide backbone and provide additional potential
hydrogen-bond acceptors and donors.
Fig. 3. ThT inhibition and reversal data. The data (A and B) show the averaged effect of different stoichiometries of peptides KAT, L2P1a, L2P1b, L2P2a and
L2P2b on the aggregation of 50 mM Ab1 – 42.(at 3 days for the inhibition assay and at 6 days for reversal assay). Shown also are CD spectra for inhibition and
reversal samples at 3 days post-mix. The assay is performed at 10 mM Ab1 – 42 concentration.
N.Acerra et al.
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signal by a comparable amount. At increasingly lower sub-
stoichiometric ratios, we observed progressively reduced activ-
ity consistent with a general dose dependency (see
Supplementary information).
To measure the effect on the reversal of preformed fibrils,
the peptides were added after 3 days of Ab1 – 42 fibril growth.
The ThT assay results showed a similar reduction in bound
ThT as the inhibition assays, suggesting that peptides are able
to bind Ab1 – 42 and reverse its aggregation. The positive
control peptide (iAb5) again demonstrated a similar reduction
in ThT binding, suggesting that PCA selected peptides
compare favourably. Interestingly, the degree of inhibition and
reversal tended to zero as the Ab1 – 42 : peptide stoichiometry
was reduced (see Supplementary information). At sub-
stoichiometric ratios as the peptide dose tend towards zero, the
progressively reduced activity observed again demonstrated a
dose dependency (see Supplementary information).
CD demonstrates a reduction in b-sheet content
Since amyloid fibrils are predominately b-sheet, we have used
CD spectroscopy to provide an endpoint characterisation of
the aggregates formed once ThT experiments were complete.
The data presented on the right-hand side of Fig. 3 show
spectra with a single negative peak at 218 nm, consistent with
b-sheet structure. As predicted from the ThT data above the
amount of b-structure decreased in inhibition experiments
(stoichiometry of 1 : 1) 3 days after incubating Ab1 – 42 with
peptides KAT, L2P1b and the positive control iAb5 sequence.
In agreement with the ThT data, there is a decrease in b-signal
with peptides relative to Ab1 – 42 alone for inhibition and rever-
sal experiments. As expected, the iAb5 peptide also led to a
reduced b-signal. Using information in this way may help to
derive and combine peptides that have different antagonist
properties and are therefore synergistic when administered in
combination. It should be noted that the loss in CD signal in-
tensity for Ab incubated with PCA-derived peptides is unlike-
ly to be attributed to increased aggregation or consequent
amyloid precipitation. This is because any peptides leading to
increased precipitation from amyloid-structured insoluble
deposits would also generate large increases in ThT binding.
In addition, these deposits would be clearly observed in both
TEM and OAF imaging experiments, where solutions were
thoroughly vortexed prior to loading.
TEM shows a reduction in amyloid fibres
Imaging experiments were performed on selected samples of
Ab1–42 with and without peptides to assess the presence of
fibrils and their morphology (Supplementary Fig. S1). Samples
were derived from those used in ThT experiments as described
in the materials and methods section, to allow for the direct
comparison of results. Fibrils for Ab1–42 were observed with a
diameter of 10 nm (Supplementary Fig. S1). Addition of
peptide caused a loss of observed fibrils, supporting the
reduction in ThT binding experiments. Smaller poorly defined
particles could be observed for 1 : 1 mixtures with KAT and
L2P1a. No fibrils were observed for 1 : 1 mixtures with L2P1b,
L2P1a or iAb5.
Fluorescence microscopy indicates a reduction in the quantity
of large amyloid fibres
Samples used in ThT and CD experiments were also imaged
using OAF microscopy for both inhibition and reversal experi-
ments (Kad et al., 2010 ). To prevent bias towards any one
sample, the experiment was carried out blind. This technique
allows for surface associated and stacked aggregates of
amyloid fibres to be directly imaged. It was therefore possible
to assess the amount of protein deposited as amyloid and its
morphology. For the reversal assay, Fig. 4 shows representa-
tive images of Ab1 – 42 deposited onto the surface, as well as
the effect of peptides added after 3 days incubation of Ab1 – 42
alone. To further quantify the amount of amyloid deposited,
we analysed the mean fluorescence value for each condition
using ImageJ (NIH, USA) over a number of randomly chosen
256  256 regions and found a similar correlation. Consistent
with ThT data, KAT demonstrates a major loss of fibrils
present in the Ab1 – 42 sample, but indicates a large change in
morphology and that some smaller deposits do remain, with
others either removing fibrils or changing their morphology.
Fig. 4. OAF microscopy. During reversal experiments, Ab1 – 42 was grown alone for 3 days, after which peptide was added at a stoichiometry of 1 : 1 and followed
by a further 3 day incubation to assay for peptide-induced reversal of amyloid deposition. Each sample was then imaged by fluorescence microscopy and panels
showing representative images obtained. To quantify amyloid deposition the mean grey value over a 256  256 area randomly chosen for five separate images is
plotted as fluorescence intensity. Each data point is scaled to overcome the ‘background noise’ by taking Ab (1 : 0) as the maximum and iAb5 as the minimum (i.e.
(signal-iAb5)/(Ab-iAb5)). This defines the range over the positive and negative controls. It can be clearly observed that all peptides except L2P2a are strongly
inhibitory for this reversal assay. The scale bars represent a distance of 2 mm. OAF microscopy data for inhibition experiments are shown in Supplementary
Fig. S2.
Intracellular library selected Ab interacting peptides
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OAF microscopy data for inhibition experiments demon-
strated that fibrils are present in Ab1 – 42, L2P1a and L2P1b
samples, with others showing strongly diminished levels of
ThT bound protein (Supplementary Fig. S2). Taken collective-
ly OAF, TEM, ThT and CD data suggest that KAT is more ef-
fective at inhibiting amyloid formation, while L2P1a is more
effective at reversal.
Ab slows bacterial cell growth
The effect of peptides on the growth of E.coli harbouring
Ab1 – 42-DHFR2 target and peptide-DHFR1 fusion plasmids
as present in the final PCA selection round was ascertained.
Cells were grown from a starting OD600 of 0.02 under PCA
conditions in M9 containing Amp, Cm, Kan, trimethoprim
and IPTG for protein expression. Cell growth rates were conse-
quently monitored over a period of 4 days as an indicator of
cell health and efficacy of peptide binding (Fig. 5). Cells
expressing Ab1 – 42 þ Ab1 – 42 (dark blue line) were found to
grow poorly relative to a non-toxic control (expressing cJun þ
FosW (Mason et al., 2006)—black line). This is likely due to
Ab1 – 42 self-associating (Sharpe et al., 2005) despite being
soluble in western blotting experiments (see Supplementary
Fig. S4), suggesting that the molecule populates a toxic and
soluble oligomeric state during PCA. Therefore, this offers a
method to directly assess the efficacy of an interacting peptide.
The growth rate of cells expressing Ab1 – 42 in the presence of
KAT (red line), L2P1 (purple line) or L2P2 (green line) were
much improved relative to Ab1 – 42 expressed in isolation, indi-
cating the toxicity of Ab1 – 42 self-association is reduced by ex-
pression of the PCA selected ‘winner’ sequences. The order of
improved growth was KAT . L2P2 . L2P1. After 4 days of
growth all three converged on OD600 values of 0.5, much
greater than 0.1 for cells expressing Ab1 – 42 þ Ab1 – 42. The
same experiment was repeated with Ab25 – 35 used in the PCA
library screening and selection and again demonstrated that
cells expressing Ab25 – 35 þ Ab25 – 35 grew at reduced rates
relative to cells expressing Ab25 – 35 in the presence of KAT,
L2P1 or L2P2 (Supplementary Fig. S6).
Discussion
A PCA approach has been combined with semi-rational design
and peptide library screening to identify molecules capable of
binding to Ab, lowering amyloid levels and increasing bacter-
ial growth rates. By focusing libraries around the Ab29 – 35 se-
quence we have identified small peptides capable of binding to
the Ab25 – 35 region that is known to aggregate in isolation.
Selection was iterative; the second library used the first PCA
‘winner’ as a design template, enabling a second round of pep-
tides to be developed with no resemblance to the Ab29 – 35 tem-
plate. Collectively the data demonstrate that all peptides
reduce amyloid levels; information from ThT and CD indicate
that PCA-derived peptides are able to prevent Ab1 – 42 fibril
formation and reverse preformed fibrils. In general, the most
effective molar ratio was 1 : 1, perhaps reflecting the expres-
sion system where selection would be predicted to occur at ap-
proximately equimolar levels of peptide : Ab. In addition, as
the molar ratio was progressively lowered the reduction in ThT
bound was lowered as well, indicating an associated dose de-
pendency.
A number of approaches were employed to study the effect-
iveness of the peptides. OAF and TEM verified the observa-
tions from ThT and CD. These imaging experiments identified
much less amyloid and a distinct change in the fibril morph-
ology, indicating that peptides cause a significant reduction in
size of oligomeric species produced. Since ThT binds to many
different oligomeric forms of Ab and CD measures only an
averaged global signal of b-sheet content, direct imaging
offers the best indication of an effect upon Ab. OAF micros-
copy experiments suggest that KAT and L2P2b are capable of
substantially preventing amyloid formation, but that all pep-
tides result in reduced size assemblies, demonstrating that to
Fig. 5. Growth competition assays with Ab1 – 42 target. To confirm that Ab1 – 42-DHFR2 impedes the growth rates of E.coli, and to ascertain that peptides are able
to reverse the effect of Ab1 – 42-DHFR2 in causing reduced bacterial growth rates, growth competition experiments were undertaken in M9 liquid media as for
growth competition experiments the during PCA selection process. In these experiments cells expressed either (i) Ab1 – 42-DHFR2 þ Ab1 – 42-DHFR1 (dark blue),
(ii) a non-toxic control consisting of cJun-DHFR2 þ FosW-DHFR1 (black), (iii) Ab1 – 42-DHFR2 þ peptide-DHFR1 (red, green, purple) in E.coli. All three
peptides led to significant growth rates relative to (i) in the order KAT . L2P2. L2P1. For growth competition assays with Ab35 – 35 target see Supplementary
Fig. S6.
N.Acerra et al.
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varying degrees all are able to reverse formation of preformed
fibrils. Bacterial growth experiments under PCA conditions
showed increased growth rates relative to cells expressing the
self-associating Ab1 – 42 or Ab25 – 35 in isolation, indicating
that binding of peptides to their Ab targets reduces the overall
cellular toxicity. Therefore, overall the data support the hy-
pothesis that amyloid deposits are being broken down into
smaller species and that peptides derived in this study
compare favourably with the previously reported iAb5 inhibi-
tor (Soto et al., 1998). The fact that some ThT fluorescence
remains, along with b-sheet signal in the CD and some depos-
its are via imaging, suggests that peptides bind to oligomeric
rather than monomeric Ab, which would not be predicted to
represent a highly structured binding epitope. In the MTT
assay, no peptide improved cell viability to any significant
amount (Supplementary Fig. S8). However, it should be noted
that since PCA is undertaken inside bacteria it is possible that
intracellular selection of peptides that are non-toxic to E.coli
may not be as effective when transferred into a mammalian
cell system. There, exposure to different off-target interactions
and a different protease pool will occur. In addition it is neces-
sary for the peptide to function in the extracellular space,
where Ab is known to aggregate in the brain. This may
explain the discrepancy between growth rates in E.coli and ef-
ficacy in MTT experiments on peptides incubated with PC12
cells. Nonetheless these data clearly show that amyloid-PCA
is capable of deriving peptides that can interfere with amyloid
fibrilisation; further refinement of peptide properties could
allow for the breakdown of these species into benign frag-
ments.
With the first library winner used as a design template for
the second library, it was hoped that an improvement in inhib-
ition properties would be seen; however, all of the biophysical
and biochemical data suggest no further improvement.
Nonetheless, it may be possible that the future derivation of
first generation peptides could show improvements in such
second generation libraries. Also, further modifications
employing iterations of ‘Truncation, Randomisation and selec-
tion’ (TRaSe) (Crooks et al., 2011) may assist in arriving at
molecules of reduced size, but comparable efficacy while ful-
filling some of the traditional requirements for small mole-
cules (Lipinski et al., 2001; Lipinski, 2003; Mason, 2010).
Finally, although we have not directly quantified the affinity of
binding, drugs with low binding affinities (i.e. mM rather than
nM–pM) may still hold considerable therapeutic promise,
since aggregation is a kinetic process and therefore binding to
correctly folded molecules or species present during the initial
nucleation step will considerably slow amyloid conversion
rates. Thus in patients newly diagnosed with AD, administer-
ing drugs that target small soluble oligomers may aid in
slowing the conversion to insoluble plaques; for example,
antibodies that target Ab dimers have be shown to be
effective in preventing inhibition of long-term potentiation
(Klyubin et al., 2008).
In this study, we have developed a straightforward high
throughput intracellular bacterial selection approach to derive
a range of peptides that bind Ab1 – 42. By using a number of
techniques, we demonstrate the differential capacity of each
peptide to prevent and/or reverse fibril formation. Although at
present the effect of these peptides is modest, they provide a
starting point for further refinement in more complex mamma-
lian systems. Using this approach it is envisaged that peptide
inhibitors can be developed with reduced protease susceptibil-
ity and smaller size. Both may be achieved via the introduction
of non-natural amino acids or main-chains, or via introduction
of non-peptidic restraints that mimic or reinforce the natural
secondary structure (Mason, 2010; Rao et al., 2013). Other de-
sirable properties such as improved blood–brain barrier pene-
tration might be achieved via fusion to cell penetrating
peptides (Morris et al., 2008) or by decreasing the molecular
weight (Lipinski et al., 2001). All of these strategies may offer
promise in the search for molecules targeted at slowing or
even preventing the onset of AD.
Supplementary data
Supplementary data are available at PEDS online.
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